Dose optimisation of favipiravir against RNA viruses using physiologically-based pharmacokinetic modelling.
William HJ Wood, Henry E. Pertinez, Tim Rowland, Andrew Owen, Tom Fletcher, Saye Khoo
This study optimizes favipiravir doses against RNA viruses using physiologically-based pharmacokinetic modeling, showing safe dosing ranges and effects of chronic kidney disease.
bioRxiv · Jun 26, 2026 · PreprintPharmacology & Toxicology